x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011728
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP, IF, Flow Cyt |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ALDH1A1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ALDH1A1 |
| UniProt No. | P00352 |
| Gene ID | 216 |
| Gene Description | The aldehyde dehydrogenase family is a large group of enzymes that oxidize aldehydes formed through metabolic processes to their carboxylic acids. ALDH1A1 is a liver cytosolic isoform of acetaldehyde dehydrogenase and is involved in the major pathway of alcohol metabolism along with alcohol dehydrogenase. ALDH1A1 is also known as retinal dehydrogenase 1 and is involved in retinol metabolism, converting retinol to retinoic acid. Recent studies suggest that control of retinoid signaling through ALDH1A1 may influence hematopoietic stem cell differentiation. There has been recent interest in ALDH1 isoforms as predictive biomarkers in disease. Several studies have suggested that ALDH1A1 is a potential marker for cancer stem cells and chemoresistance in several tumor types, such as melanoma, lung cancer, and glioblastoma. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
